NASDAQ:ARQT

Arcutis Biotherapeutics (ARQT) Stock Forecast, Price & News

$5.38

-0.33 (-5.78%)

(As of 09/22/2023 ET)

Compare

Today's Range: $5.28
▼
$5.84
50-Day Range: $5.71
▼
$10.98
52-Week Range: $5.28
▼
$20.64

Volume: 947,958 shs
Average Volume: 1.09 million shs
Market Capitalization: $331.68 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $43.43

Arcutis Biotherapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 707.2% Upside
$43.43 Price Target
Short Interest: Bearish
27.89% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.80
Based on 5 Articles This Week
Insider Trading: Selling Shares
$11,299 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($4.77) to ($3.92) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.10 out of 5 stars

Medical Sector

491st out of 968 stocks

Pharmaceutical Preparations Industry

214th out of 445 stocks

3.5

Analyst's Opinion

Consensus Rating
Arcutis Biotherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $43.43, Arcutis Biotherapeutics has a forecasted upside of 707.2% from its current price of $5.38.
Amount of Analyst Coverage
Arcutis Biotherapeutics has only been the subject of 3 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
27.89% of the float of Arcutis Biotherapeutics has been sold short.
Short Interest Ratio / Days to Cover
Arcutis Biotherapeutics has a short interest ratio ("days to cover") of 11.3, which indicates bearish sentiment.
Change versus previous month
Short interest in Arcutis Biotherapeutics has recently decreased by 19.22%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Arcutis Biotherapeutics does not currently pay a dividend.
Dividend Growth
Arcutis Biotherapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ARQT.

2.7

News and Social Media Coverage

News Sentiment
Arcutis Biotherapeutics has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Arcutis Biotherapeutics this week, compared to 3 articles on an average week.
Search Interest
Only 9 people have searched for ARQT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Arcutis Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Arcutis Biotherapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $11,299.00 in company stock.
Percentage Held by Insiders
20.70% of the stock of Arcutis Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Arcutis Biotherapeutics are expected to grow in the coming year, from ($4.77) to ($3.92) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Arcutis Biotherapeutics is -0.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Arcutis Biotherapeutics is -0.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Arcutis Biotherapeutics has a P/B Ratio of 1.56. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Arcutis Biotherapeutics (NASDAQ:ARQT) Stock

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical formulation of ivarmacitinib designed to reach deeper into the skin in order to treat alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

ARQT Price History

30 days | 90 days | 365 days | Advanced Chart

ARQT Stock News Headlines

September 21, 2023 | americanbankingnews.com

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Receives $44.75 Average PT from Analysts

September 19, 2023 | markets.businessinsider.com

Arcutis Biotherapeutics Reveals Promising Data From Lead Drug In Pediatric Patients With Atopic Dermatitis

September 22, 2023 | Stansberry Research (Ad)

Bank Collapse Causes Gold Prices to Soar

Silicon Valley Bank was the second-largest bank in American history to fail, and investors have started piling into the safety and security of gold. But if you're not taking advantage of a little-known way to invest for around $5 today, you're missing out.

September 19, 2023 | msn.com

Arcutis posts late-stage win for atopic dermatitis therapy in children

September 19, 2023 | markets.businessinsider.com

Goldman Sachs Sticks to Its Buy Rating for Arcutis Biotherapeutics (ARQT)

September 19, 2023 | finance.yahoo.com

Arcutis Announces Positive Results from INTEGUMENT-PED Pivotal Phase 3 Trial of Roflumilast Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5

September 13, 2023 | markets.businessinsider.com

JonesTrading Reaffirms Their Buy Rating on Arcutis Biotherapeutics (ARQT)

September 13, 2023 | finance.yahoo.com

Arcutis (ARQT) Files sNDA for Zoryve in Atopic Dermatitis, Stock Up

September 22, 2023 | Stansberry Research (Ad)

Bank Collapse Causes Gold Prices to Soar

September 12, 2023 | finance.yahoo.com

Arcutis Submits Roflumilast Cream 0.15% Supplemental New Drug Application to the FDA for the Treatment of Atopic Dermatitis in Adults and Children Ages 6 Years and Older

September 7, 2023 | markets.businessinsider.com

Arcutis Reports Results From INTEGUMENT-OLE Long-term Extension Trial Of Roflumilast Cream 0.15%

September 7, 2023 | finance.yahoo.com

Why Shares of Arcutis Biotherapeutics Fell This Week

September 7, 2023 | finance.yahoo.com

Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.15% Showing Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Mild to Moderate Atopic Dermatitis (AD)

August 31, 2023 | finance.yahoo.com

Arcutis Biotherapeutics Publishes Annual Environmental, Social, and Governance (ESG) Report

August 29, 2023 | finance.yahoo.com

Arcutis Launches First Television Ad for ZORYVE® (Roflumilast) Cream 0.3%

August 23, 2023 | markets.businessinsider.com

JonesTrading Sticks to Their Buy Rating for Arcutis Biotherapeutics (ARQT)

August 19, 2023 | finanznachrichten.de

Arcutis Biotherapeutics, Inc.: Arcutis Appoints Interim Chief Financial Officer (CFO)

August 18, 2023 | msn.com

Arcutis CFO Scott Burrows to leave the company

August 18, 2023 | finance.yahoo.com

Arcutis Appoints Interim Chief Financial Officer (CFO)

August 13, 2023 | finance.yahoo.com

Broker Revenue Forecasts For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Are Surging Higher

August 11, 2023 | finance.yahoo.com

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported, And Analysts Assigned A US$41.57 Price Target

August 11, 2023 | msn.com

TD Cowen Maintains Arcutis Biotherapeutics (ARQT) Outperform Recommendation

August 11, 2023 | markets.businessinsider.com

7 Analysts Have This to Say About Arcutis Biotherapeutics

August 10, 2023 | technews.tmcnet.com

Arcutis and Huadong Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Greater China and Southeast Asia

August 10, 2023 | finance.yahoo.com

Arcutis and Huadong Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Greater China and Southeast Asia

August 9, 2023 | markets.businessinsider.com

JonesTrading Remains a Buy on Arcutis Biotherapeutics (ARQT)

August 9, 2023 | finanznachrichten.de

Arcutis Biotherapeutics, Inc.: Arcutis Announces Second Quarter 2023 Financial Results and Provides Business Update

See More Headlines

Receive ARQT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcutis Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

ARQT Company Calendar

Last Earnings: 8/08/2023
Today: 9/22/2023
Next Earnings (Estimated): 11/14/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ARQT
CUSIP: N/A
CIK: 1787306
Web: www.arcutis.com
Phone: 805-418-5006
Fax: N/A
Employees: 268
Year Founded: 2016

Price Target and Rating

Average Stock Price Forecast: $43.43
High Stock Price Forecast: $57.00
Low Stock Price Forecast: $22.00
Forecasted Upside/Downside: +707.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($5.54)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-311,460,000.00
Net Margins: -2,837.94%
Pretax Margin: -2,837.94%
Return on Equity: -188.88%
Return on Assets: -79.79%

Debt

Debt-to-Equity Ratio: 2.48
Current Ratio: 8.43
Quick Ratio: 8.14

Sales & Book Value

Annual Sales: $3.69 million
Price / Sales: 89.89
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.44 per share
Price / Book: 1.56

Miscellaneous

Outstanding Shares: 61,650,000
Free Float: 48,892,000
Market Cap: $331.68 million
Optionable: Not Optionable
Beta: 0.64

Social Links

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Mr. Todd Franklin Watanabe M.A. (Age 55)
Pres, CEO & Director
Comp: $1.01M

Dr. Bhaskar Chaudhuri Ph.D. (Age 68)
Co-Founder & Independent Director
Comp: $59.67k

Mr. Masaru Matsuda Esq. (Age 52)
J.D., Sr. VP, Gen. Counsel & Corp. Sec.
Comp: $626.22k

Dr. Patrick E. Burnett M.D. (Age 51)
Ph.D., Sr. VP & Chief Medical Officer
Comp: $689.95k

Mr. John W. Smither CPA (Age 70)
Interim CFO & Principal Accounting Officer

Ms. Patricia A. Turney (Age 56)
Sr. VP of Operations

Mr. Rajvir Madan
Chief Digital & Technology Officer

Mr. Eric McIntyre
Head of Investor Relations

Ms. Courtney Barton (Age 40)
VP and Chief Compliance Officer & Privacy Officer

Ms. Amanda Sheldon
Head of Corp. Communications

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ARQT Stock - Frequently Asked Questions

Should I buy or sell Arcutis Biotherapeutics stock right now?: 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arcutis Biotherapeutics in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ARQT shares.
View ARQT analyst ratings or view top-rated stocks.
What is Arcutis Biotherapeutics' stock price forecast for 2023?: 6 Wall Street analysts have issued 12-month price objectives for Arcutis Biotherapeutics' stock. Their ARQT share price forecasts range from $22.00 to $57.00. On average, they predict the company's stock price to reach $43.43 in the next year. This suggests a possible upside of 707.2% from the stock's current price.
View analysts price targets for ARQT or view top-rated stocks among Wall Street analysts.
How have ARQT shares performed in 2023?: Arcutis Biotherapeutics' stock was trading at $14.80 at the start of the year. Since then, ARQT shares have decreased by 63.6% and is now trading at $5.38.
View the best growth stocks for 2023 here.
Are investors shorting Arcutis Biotherapeutics?: Arcutis Biotherapeutics saw a drop in short interest in August. As of August 31st, there was short interest totaling 12,480,000 shares, a drop of 19.2% from the August 15th total of 15,450,000 shares. Based on an average trading volume of 1,100,000 shares, the short-interest ratio is presently 11.3 days. Currently, 27.9% of the shares of the stock are short sold.
View Arcutis Biotherapeutics' Short Interest.
When is Arcutis Biotherapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our ARQT earnings forecast.
How were Arcutis Biotherapeutics' earnings last quarter?: Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) announced its quarterly earnings data on Tuesday, August, 8th. The company reported ($1.16) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.22) by $0.06. The firm earned $5.19 million during the quarter, compared to analyst estimates of $4.87 million. Arcutis Biotherapeutics had a negative trailing twelve-month return on equity of 188.88% and a negative net margin of 2,837.94%.
What ETF holds Arcutis Biotherapeutics' stock ?: Virtus LifeSci Biotech Clinical Trials ETF holds 10,172 shares of ARQT stock, representing 0.89% of its portfolio.
What other stocks do shareholders of Arcutis Biotherapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Arcutis Biotherapeutics investors own include Black Diamond Therapeutics (BDTX), Pfizer (PFE), Akero Therapeutics (AKRO), Advanced Micro Devices (AMD), Applied Therapeutics (APLT), Aptinyx (APTX), BioNTech (BNTX), ServiceNow (NOW), Qualys (QLYS) and AbbVie (ABBV).

When did Arcutis Biotherapeutics IPO?: (ARQT) raised $125 million in an initial public offering (IPO) on Friday, January 31st 2020. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs, Cowen and Guggenheim Securities acted as the underwriters for the IPO and Cantor was co-manager.
What is Arcutis Biotherapeutics' stock symbol?: Arcutis Biotherapeutics trades on the NASDAQ under the ticker symbol "ARQT."
Who are Arcutis Biotherapeutics' major shareholders?: Arcutis Biotherapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include State Street Corp (8.48%), Rubric Capital Management LP (7.92%), Jennison Associates LLC (6.99%), BlackRock Inc. (6.86%), Polar Capital Holdings Plc (5.07%) and Marshall Wace LLP (3.76%). Insiders that own company stock include Bhaskar Chaudhuri, David W Osborne, Howard G Welgus, Howard G Welgus, John W Smither, Masaru Matsuda, Orbimed Advisors Llc, Patricia A Turney, Patrick Burnett, Scott L Burrows and Todd Franklin Watanabe.
View institutional ownership trends.
How do I buy shares of Arcutis Biotherapeutics?: Shares of ARQT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Arcutis Biotherapeutics' stock price today?: One share of ARQT stock can currently be purchased for approximately $5.38.
How much money does Arcutis Biotherapeutics make?: Arcutis Biotherapeutics (NASDAQ:ARQT) has a market capitalization of $331.68 million and generates $3.69 million in revenue each year. The company earns $-311,460,000.00 in net income (profit) each year or ($5.54) on an earnings per share basis.
How many employees does Arcutis Biotherapeutics have?: The company employs 268 workers across the globe.
How can I contact Arcutis Biotherapeutics?: Arcutis Biotherapeutics' mailing address is 2945 TOWNSGATE ROAD SUITE 110, WESTLAKE VILLAGE CA, 91361. The official website for the company is www.arcutis.com. The company can be reached via phone at 805-418-5006 or via email at ir@arcutis.com.

This page (NASDAQ:ARQT) was last updated on 9/22/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial